Stockwinners Market Radar for June 27, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

19:38 EDT DaVita COO buys $1.55M in common stock - In a regulatory filing, DaVita disclosed that its COO Michael Staffieri bought 20K shares on June 23 in a total transaction size of $1.55M.

19:31 EDT Cybin announces additional Adelia milestone achievement - Cybin "announces that Adelia Therapeutics, a wholly-controlled subsidiary of Cybin, has achieved the milestone identified as Y2, Q3 as contemplated by the terms of a contribution agreement dated December 4, 2020 among Cybin, Cybin Corp., Cybin US Holdings Inc. , a wholly-controlled subsidiary of Cybin, and all of the previous shareholders of Adelia."

19:06 EDT Exxon Mobil CEO sees resurgence in fossil fuel production, FT reports - Exxon Mobil CEO Darren Woods told the Financial Times that he anticipates a resurgence of investment in fossil fuel production, blaming rising oil and gas prices on an "optimistic view" about how rapidly the energy transition can happen. Woods said the pressure to cut emissions by lowering output before addressing demand had left the world struggling to meet energy needs, the FT's Tom Wilson and Justin Jacobs report. Reference Link

18:40 EDT Enphase Energy CEO sells $7.73M in common stock - In a regulatory filing, Enphase Energy disclosed that its CEO Badrinarayanan Kothandaraman sold 38.9K shares of common stock on June 23rd in a total transaction size of $7.73M.

18:09 EDT Citizens Financial raises share repurchase authorization to $1B - Citizens Financial Group announces key aspects of its 2022 Capital Plan, which includes increasing the company's common share repurchase authorization to $1B. The company's announcement follows publication on June 23 by the Board of Governors of the Federal Reserve System of the results from its DFAST stress tests and communication to Citizens of its preliminary Stress Capital Buffer of 3.4%, effective October 1. Citizens has concluded that its proposed capital distributions under the Plan would be consistent with this preliminary SCB requirement over the relevant quarters. Specifically, Citizens announces that its Board of Directors increased the authorization of common share repurchases to $1B, which is an increase of $545M above the $455M of capacity remaining under the prior $750M January 2021 authorization. Furthermore, Citizens' Board of Directors will consider an increase in the company's quarterly common stock dividend for the third quarter.

17:52 EDT Nike says taking 'cautious approach' to greater China in FY23 - Says longer term, growth potential in China is "significant." Expects marketplace to be "promotional" in China in Q1.

17:32 EDT Citi to maintain current common dividend of 51c per share in Q3 - Citi plans to maintain the current common dividend of 51c per share in the third quarter of 2022. Citi's quarterly common dividend is subject to approval by Citi's Board of Directors and the latest financial and macroeconomic conditions.

17:21 EDT Nike says 'better positioned' now than before pandemic - Continues to see strong consumer demand. Says 'very confident' in growth strategy and long-term outlook. Sees "special opportunity" in women's business and plans to focus on it going forward. Comments taken from Q4 earnings conference call.

17:08 EDT Instagram introduces new ways to verify age - Instagram introduced certain enhancements to its age verification process in an earlier blog posting. Instagram said in part: "Starting today, we're testing new options for people on Instagram to verify their age, starting with people based in the US. If someone attempts to edit their date of birth on Instagram from under the age of 18 to 18 or over, we'll require them to verify their age using one of three options: upload their ID, record a video selfie or ask mutual friends to verify their age. We're testing this so we can make sure teens and adults are in the right experience for their age group. We are also partnering with Yoti, a company that specializes in online age verification, to help ensure people's privacy...In addition to having someone upload their ID, we're testing two new ways to verify a person's age:Video Selfie: You can choose to upload a video selfie to verify your age. If you choose this option, you'll see instructions on your screen to guide you.Social Vouching: This option allows you to ask mutual followers to confirm how old you are. The person vouching must be at least 18 years old, must not be vouching for anyone else at that time and will need to meet other safeguards we have in place...We're partnering with Yoti, a company that offers privacy-preserving ways to verify age. Yoti is verified by the Age Check Certification Scheme and is the leading age verification provider for several industries around the world including social media, gaming and age restricted e-commerce." Reference Link

17:06 EDT Aviat proposes to acquire Cergaon Networks for $2.80 per share in cash - Aviat Networks (AVNW) announced it has submitted a nonbinding proposal to acquire all the outstanding shares of Ceragon Networks Ltd. (CRNT) that it does not already own for $2.80 per share in cash. Aviat holds more than 5% of Ceragon's outstanding shares as of June 24, 2022, making it Ceragon's third largest shareholder. Under the terms of the proposal, which was delivered to Ceragon's Board of Directors, Ceragon shareholders would receive $2.80 per share in cash, providing them with immediate and certain value. Aviat also remains open to offering a portion of the consideration in Aviat stock to allow shareholders the opportunity to participate in the significant upside of the combined company. The proposal represents a substantial premium of 34% to the closing price of Ceragon shares on June 27, 2022 and a 51% premium to the 60-day volume weighted average trading price of Ceragon shares as of June 24, 2022. "Over the past year, we have sought to engage on numerous occasions with Ceragon's Board and management team to negotiate terms for a transaction that we are confident would deliver meaningful near- and long-term value for shareholders of both companies," said Aviat President and CEO Peter Smith. "We have twice attempted to reasonably address concerns voiced by Ceragon, and have met only with delay and rejection. Along with Aviat's Chairman, I traveled to Israel last week to meet in person with Ceragon's Chairman, CEO, and a member of its Board. They refused to engage with us in constructive discussions, instead making further demands for unorthodox and off-market provisions that seem intended only to delay, leaving us with no other option but to make Ceragon shareholders aware of our proposal."

17:05 EDT Goldman Sachs to raise quarterly dividend to $2.50 per share from $2.00 - On Thursday, June 23, the Federal Reserve notified the firm of the Stress Capital Buffer for The Goldman Sachs Group, Inc. of 6.3%, resulting in a Standardized Common Equity Tier 1 ratio requirement of 13.3%, which will become effective on October 1, 2022. Supported by the movement toward more durable revenues, the firm's capital plan includes an increase in the common stock dividend from $2.00 to $2.50 per share, subject to approval by the firm's Board of Directors at the customary third quarter meeting. "Our client-oriented strategy will continue to diversify the firm's franchise and provide a strengthened return profile," said Chairman and CEO David Solomon. "We will continue to dynamically manage capital and remain well positioned to support our clients."

17:02 EDT Wells Fargo raises quarterly dividend to 30c from 25c per share - Wells Fargo "expects to increase its third quarter 2022 common stock dividend to $0.30 per share from $0.25 per share, subject to approval by the Company's Board of Directors at its regularly scheduled meeting in July."

16:56 EDT Northern Trust announces CCAR results, plans to increase quarterly dividend - Northern Trust commented on the results of the Federal Reserve's 2022 Comprehensive Capital Analysis and Review and announced plans to increase its quarterly common stock dividend from 70c to 75c per common share, beginning in the third quarter. Based on the CCAR 2022 results, Northern Trust will be subject to a preliminary stress capital buffer of 2.5%, which is unchanged from the current level. The SCB will be effective from October 1, 2022, to September 30, 2023, and will equate to a minimum common equity tier 1 ratio of 7%. The common stock dividend is subject to approval from the Corporation's Board of Directors.

16:54 EDT JPMorgan maintaining dividend following CCAR stress test results - JPMorgan Chase & Co. announced that it has completed the Federal Reserve's 2022 Comprehensive Capital Analysis and Review, CCAR, stress test process. The Firm's indicative Stress Capital Buffer, SCB, requirement is 4.0%, up from the current 3.2%, and the Firm's Standardized Common Equity Tier 1 capital ratio requirement including regulatory buffers is 12.0%, up from the current 11.2%. The Federal Reserve will provide the Firm with its final SCB requirement by August 31, 2022, and that requirement will become effective on October 1, 2022 and will remain in effect until September 30, 2023. JPMorgan Chase's board intends to maintain the current quarterly common stock dividend of $1.00 per share for Q3 of 2022 in light of higher future capital requirements. The firm's quarterly common stock dividends are subject to approval by the board at the customary times that those dividends are declared.

16:47 EDT Jefferies Financial board authorizes repurchase of up to $250M in common stock

16:46 EDT PNC Financial announces CCAR results - The PNC Financial Services Group last week received the results of the Federal Reserve's 2022 Comprehensive Capital Analysis and Review, CCAR. The Federal Reserve's CCAR disclosure included its estimate of PNC's minimum capital ratios for the period from Q1 of 2022 through Q1 of 2024 under the hypothetical Supervisory Severely Adverse scenario. Based on PNC's strong results, PNC's Stress Capital Buffer, SCB, for the four-quarter period beginning Oct. 1, 2022 is 2.9%. PNC's Common Equity Tier 1, CET1, ratio significantly exceeds the regulatory minimum (4.5%) plus its SCB, reflecting the company's strong capital levels entering 2022 following the integration of BBVA USA. Earlier this quarter, the board authorized a new repurchase framework, under the already approved authorization for repurchases of up to 100M common shares of which approximately 64% were still available for repurchase as of March 31, 2022. This framework and our SCB results allow for the continuation of our recent quarterly dollar average share repurchase levels, as well as the flexibility to increase those levels should conditions warrant. PNC's common share repurchases may be executed in privately negotiated transactions or through the open market, including under Rule 10b5-1 plans. As previously disclosed, on April 1, the PNC board raised the quarterly cash dividend on common stock to $1.50 per share, an increase of 25c per share, or 20%, which became effective with the May 5 dividend payment.

16:37 EDT Regions Financial considering dividend boost following stress test results - The Federal Reserve has communicated to Regions Financial Corp. that the company exceeded all minimum capital levels under the Federal Reserve's Supervisory Stress Test. Regions' preliminary Stress Capital Buffer requirement for Q4 of 2022 through Q3 of 2023, as determined by the Federal Reserve, will be floored at 2.5%. Additionally, Regions' board will consider an increase in Regions' quarterly common stock dividend, effective for Q3 of 2022, at the board's regularly scheduled meeting in July 2022.

16:36 EDT BNY Mellon raises quarterly dividend 9% to 37c per share - On June 23, 2022, the Federal Reserve released the results of its 2022 bank stress tests, which demonstrate the resilience and strength of BNY Mellon's business model and capital position. The Federal Reserve also notified the company that its preliminary Stress Capital Buffer requirement will remain 2.5%, equal to the regulatory floor. This SCB is expected to be effective from October 1, 2022 to September 30, 2023. The company intends to increase its quarterly cash dividend on its common shares by 9% from $0.34 to $0.37 per share, commencing as early as the third quarter of 2022, subject to approval by the company's Board of Directors. The company continues to be authorized to repurchase common shares under its existing share repurchase program approved by the Board of Directors, as announced in June 2021. The timing, manner and amount of repurchases are subject to various factors, including the company's capital position and prevailing market conditions. Todd Gibbons, Chief Executive Officer of BNY Mellon said: "The Federal Reserve's 2022 bank stress tests once again show that our resilient business model and strong balance sheet are well positioned to weather periods of even severe stress while continuing to support our clients and the broader economy. As we remain committed to maintaining strong capital ratios and delivering value to our shareholders, we are pleased to announce our intention to increase our dividend in the coming quarter."

16:33 EDT Morgan Stanley raises quarterly dividend 11% to 77.5c per share - Morgan Stanley announced that it will increase its quarterly common stock dividend to $0.775 per share from the current $0.70 per share, beginning with the common dividend expected to be declared by the firm's board in the third quarter of 2022.

16:33 EDT Bank of America raises quarterly dividend 5% to 22c per share - Bank of America commented on the results of the Federal Reserve's 2022 Comprehensive Capital Analysis and Review and announced plans to increase its quarterly common stock dividend to 22c per share beginning in the third quarter of 2022. Based on the 2022 CCAR results, Bank of America's stress capital buffer will be approximately 100 bps higher than the current 2.5% level and will therefore add approximately 100 bps to our CET1 minimum requirement of 9.5%. When finalized, this new SCB will be effective from October 1, 2022 to September 30, 2023. At March 31, 2022 Bank of America had $170 billion of regulatory CET1 capital and a CET1 ratio of 10.4%. "Our responsible growth strategy over the last decade has put us in a strong position to support our clients and deliver for shareholders," said Bank of America Chair and Chief Executive Officer Brian Moynihan. "In October 2021, we renewed the Company's previously announced $25 billion common stock purchase program with $17 billion remaining as of March 31, 2022, and today we are also announcing that we expect to increase the quarterly common stock dividend by 5% to $0.22 per share." Bank of America Chief Financial Officer Alastair Borthwick added that "the 2022 annual stress test results once again support that Bank of America maintains a strong capital position to serve its customers and clients through the current economic environment and our continued discipline around risk has us well prepared for a severe economic stress scenario."

16:32 EDT State Street raises quarterly dividend 10% to 63c per share - State Street Corporation announced its preliminary stress capital buffer requirement of 2.5%, effective October 1, 2022, and the intention to increase its quarterly common stock dividend by 10% to 63c per share in the third quarter, subject to consideration and approval by its Board of Directors. State Street's calculated SCB under this year's supervisory stress test was well below the 2.5% minimum, preliminarily resulting in an SCB at that floor, which maintains our common equity tier 1 ratio requirement at 8%. The firm's capital position is strong and in the fourth quarter of 2022 it remains the company's intention to again begin its existing common share repurchase program in an amount reflecting interest rate levels and market conditions at the time.

16:31 EDT IT Tech Packaging board approves 1-for-10 reverse stock split - IT Tech Packaging announced that, its Board of Directors has approved a reverse stock split of its common stock, par value $0.001 per share at a ratio of 1-for-10. The Reverse Stock Split is expected to become effective on July 7, 2022, and the shares are expected to begin trading on the split-adjusted basis on the NYSE American under the company's existing trading symbol "ITP" at market open on July 8, 2022, upon NYSE American's approval. The new CUSIP number following the Reverse Stock Split will be46527C 209. Under Nevada Revised Statutes Section 78.207, the Company may decrease its authorized shares of its Common Stock and correspondingly decrease its number of issued and outstanding shares of Common Stock by resolution adopted by the Board of Directors, without obtaining the approval of the stockholders. The Reverse Stock Split will be effected by the Company filing a Certificate of Change pursuant to NRS Section 78.209 with the Secretary of State of the State of Nevada on the Effective Date. As a result of the filing of the Certificate, the number of shares of the Company's authorized Common Stock will be reduced from 500,000,000 shares to 50,000,000 shares and the issued and outstanding number of shares of the Company's common stock will be correspondingly decreased.

16:25 EDT Points-Plusgrade deal receives final approval from Ontario Superior Court - Points.com Inc. announced that it has obtained final approval from the Ontario Superior Court of Justice of the previously-announced plan of arrangement under section 192 of the Canada Business Corporations Act, pursuant to which a wholly-owned subsidiary of Plusgrade L.P. will acquire all of the issued and outstanding common shares of Points for $25.00 in cash per common share. Subject to the satisfaction or waiver of customary closing conditions, the parties currently anticipate that the closing of the Arrangement will occur on or about June 30, 2022.

16:18 EDT Nike reports Q4 Nike Brand revenues $11.7B, down 1% on reported basis - Revenues for the NIKE Brand were $11.7B, down 1% on a reported basis and up 3% on a currency-neutral basis, led by 20% growth in EMEA. Revenues for Converse were $593M, down 1% on a reported basis and up 3% on a currency-neutral basis, due to wholesale revenue declines offset by growth in our direct to consumer business.

16:16 EDT Nike reports Q4 NIKE Direct revenues up 11% on currency-neutral basis - Fourth quarter NIKE Direct revenues grew 7 percent on a reported basis and 11 percent on a currency-neutral basis, led by 25 percent growth in EMEA, 43 percent growth in APLA and 5 percent growth in North America, partially offset by a decline in Greater China. NIKE Brand Digital grew 15 percent on a reported basis and 18 percent on a currency-neutral basis, driven by double digit growth in APLA, North America and EMEA. NIKE-owned stores declined 2 percent on a reported basis and increased 1 percent on a currency-neutral basis.

16:13 EDT Spero falls 15% to 80c after Complete Response Letter for tebipenem

16:10 EDT Offerpad Solutions joins Russell 2000, Russell 3000 Indexes - Offerpad Solutions Inc. announced the company has joined the broad-market Russell 2000 and Russell 3000 Indexes effective today. "Membership in the Russell indexes only seven years since founding Offerpad and less than a year after becoming a public company is a great milestone. We appreciate the interest and engagement we have experienced from investors in the early days as a public company and we look forward to continuing to share our strategy to deliver long-term value going forward," said Brian Bair, Offerpad's Chairman and Chief Executive Officer.

16:08 EDT Lovesac , Joybird amicably resolve patent litigation - The Lovesac Company announced that it has reached an agreement to amicably resolve its patent litigation against Stitch Industries, dba Joybird, a unit of La-Z-Boy. The lawsuit between the parties, captioned The Lovesac Company v. Stitch Industries, Inc. dba Joybird, Case No. 2:21-cv-09904-MCS-KS alleged infringement of United States Patent Nos. 7,213,885, 7,419,220, 8,783,778, 10,123,623, 10,154,733, and 10,806,261. The parties have reached a mutually agreeable business resolution and the lawsuit has been dismissed with prejudice. The terms of the parties' agreement are confidential.

16:06 EDT SAIC names Hilary Hageman as General Counsel - Science Applications "announces the appointment of Hilary L. Hageman as Executive Vice President, General Counsel, and Corporate Secretary, effective July 11, 2022. Steven G. Mahon, SAIC's Executive Vice President, General Counsel, and Corporate Secretary since 2015, is retiring on September 30, 2022. Hageman served at SAIC as a Senior Vice President and Deputy General Counsel until 2019, when she became the General Counsel and Corporate Secretary of Cubic Corporation, a defense and transportation company."

16:03 EDT Essa Pharma provides update on Phase 1a study of EPI-7386 - ESSA Pharma presented clinical results from the Phase 1a dose escalation study of EPI-7386, ESSA's first-in-class N-terminal domain androgen receptor inhibitor, as a monotherapy for the treatment of patients with metastatic castration-resistant prostate cancer resistant to current standard-of-care therapies. The initial data from 36 patients demonstrate that EPI-7386 was well-tolerated, exhibited a favorable pharmacokinetic profile, and demonstrated initial anti-tumor activity in a heavily pretreated group of patients. ESSA expects to initiate the Phase 1b expansion study in Q3 2022. "We are pleased with the progress in advancing our novel prostate cancer candidate EPI-7386 as a monotherapy in patients with advanced mCRPC. EPI-7386's favorable safety and tolerability profile, good pharmaceutical characteristics together with both antiandrogen biological and anti-tumor activity support our decision to move into earlier lines of therapy and, importantly, study EPI-7386 in combination with second-generation antiandrogens," said Dr. David Parkinson, President and CEO of ESSA Pharma Inc. "Further, ctDNA molecular analysis in this heavily pretreated population has given us a detailed profile of genetic alterations, revealing the biological complexity of late-stage mCRPC patients but also allowing us to continue to refine the population of prostate cancer patients whose tumors are still primarily driven by the androgen receptor and therefore most likely to respond to an androgen receptor inhibitor." In the multi-center, open-label Phase 1a dose escalation study, 31 patients received EPI-7386 as oral tablets once a day in cohorts with 200 milligram increments from 200 milligrams up to 1000 milligrams. Patients in this QD group were heavily pretreated, with a median of seven lines of prior therapy for prostate cancer and four lines of therapy for metastatic mCRPC. Almost 60% of patients had been treated with prior chemotherapy. Patients entered the trial with rapidly progressive disease, as evidenced by a median prostate-specific antigen doubling time of only 2.1 months and a median ctDNA percent of 29%. Almost a third of the patients had lung, liver, or brain metastases, and an overlapping third of patients had overt neuroendocrine differentiation. The ctDNA analysis revealed that tumors in these patients had extensive non-AR associated genomic changes denoting the presence of multiple non-AR oncogenic drivers associated with late-stage prostate cancer. Following a protocol amendment, five patients were enrolled in a twice-daily dose regimen in 400 mg and 600 mg BID cohorts. The amendment excluded patients who had been treated with more than three prior lines of therapy, excluded patients with visceral metastases, and permitted only one prior line of chemotherapy.

16:02 EDT Centogene appoints Miguel Coego Rios CFO - Centogene N.V. announced the appointment of Miguel Coego Rios as Managing Director and CFO of the company, effective June 22. Coego Rios joined Centogene as EVP Finance & Legal in February 2022 and served as interim CFO as of April 1.

15:53 EDT Cedar Fair sells Great America park land to Prologis for about $310M - Cedar Fair (FUN) announced it has sold the land at its California's Great America amusement park and plans to close the park. Cedar Fair elected to sell the land to Prologis, Inc. (PLD), a Bay Area-based logistics real estate company, for approximately $310M with a lease agreement. The company will continue to operate the park for a period of up to 11 years and then will close existing park operations at the end of the lease term. The land sale, which was marketed by CBRE, was the outcome of a strategic review initiated by Cedar Fair in 2021 to explore potential avenues to maximize the value of the company's extensive asset portfolio. Cedar Fair purchased the land at California's Great America in 2019 from the City of Santa Clara after the State of California dissolved redevelopment agencies, requiring the city to cede its ownership of the property to pay off existing debt. Prior to that transaction, the company leased the land from the City for more than 40 years. Cedar Fair intends to use proceeds from the land sale transaction to accelerate progress on its strategic priorities of reducing debt to achieve its $2B target, investing in high-return projects within its portfolio such as upgrading resort properties, and reinstating a sustainable unitholder distribution. Based on the strength and pace of the recovery since reopening its parks in 2021, and due to the additional capital raised through the Great America transaction, Cedar Fair expects to reinstate quarterly unitholder distributions by the third quarter of 2022, subject to review and approval by the Cedar Fair Board of Directors.

15:09 EDT Robinhood Markets trading resumes

14:59 EDT Robinhood Markets trading halted, volatility trading pause

13:12 EDT Reliance Industries says 'unable to comment on media speculation' about Revlon - In a notice issued to the BSE Limited and the National Stock Exchange of India Limited, Reliance Industries Limited stated: "We refer to your letter / email dated June 27, 2022 seeking clarification on the news item 'India's Reliance Considers Buying Out Revlon In U.S.' which appeared in the 'www.carandbike.com' dated June 24, 2022 and would like to clarify that we are unable to comment on media speculation and rumors and it would be inappropriate on our part to do so. The Company evaluates various opportunities on an ongoing basis. Further, there is no information which has not been announced to the stock exchanges and which should have been announced by the Company in terms of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. We have made and will continue to make disclosures in compliance with our obligations under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and our agreements with the stock exchanges." Reference Link

12:34 EDT Credit Suisse to appeal Swiss Federal Criminal Court fine of CHF2M - Credit Suisse said it has "taken note" of the Swiss Federal Criminal Court's decision to impose a fine of CHF2M against Credit Suisse AG for certain historical organizational inadequacies for the period between July 2007 and December 2008. The investigation dates back more than 14 years. The bank will appeal the decision. According to media reports, the Swiss Federal Criminal Court convicted the bank of failing to prevent money-laundering by a Bulgarian cocaine trafficking group. Reference Link

12:18 EDT Clearlake Capital to sell Brightly Software to Siemens for total of $1.875B - Clearlake Capital Group announced it has entered into a definitive agreement to sell Brightly Software to Siemens AG for $1.575B of upfront cash consideration, along with $300M in cash earn-out payments, for a total of $1.875B. The transaction is expected to close in the second half of 2022 and is subject to customary closing conditions and regulatory approvals. Brightly is a software-as-a-service, or "SaaS," provider of cloud-based enterprise asset management and facility operations management. Clearlake acquired Brightly, formerly known as "Dude Solutions," in June 2019 and subsequently executed on its O.P.S. strategy by partnering with management to support the company through multiple organic and inorganic strategic initiatives. "Brightly will enable us to leapfrog to the next level of performance for buildings. With seamless data exchange between our offerings, our customers can expect enhanced efficiency, lower downtimes and maintenance costs, shorter lifecycles, better data-driven decisions and more satisfied tenants. The acquisition will speed up our target of becoming a leading software company also in infrastructure and support our vision of creating fully autonomous buildings that continuously learn from and adapt to the needs of their tenants," said Matthias Rebellius, Member of the Managing Board of Siemens and CEO of Siemens Smart Infrastructure.

12:00 EDT Weber falls -10.6% - Weber is down -10.6%, or -$1.01 to $8.55.

12:00 EDT Cion Investment rises 10.6% - Cion Investment is up 10.6%, or 87c to $9.06.

12:00 EDT Borr Drilling rises 11.9% - Borr Drilling is up 11.9%, or 66c to $6.21.

10:52 EDT BetMGM to become exclusive sportsbook of Audacy's BetQL Network - BetMGM, a sports betting and gaming entertainment company partnership between MGM Resorts (MGM) and Entain Plc (GMVHF), will become the exclusive sportsbook of the BetQL Network, Audacy's (AUD) network of sports betting content heard across its broadcast portfolio and digital platforms, the companies announced. The partnership, The BetQL Network presented by BetMGM, is an exclusive multi-year agreement that "significantly expands the current relationship between BetMGM and Audacy," the companies noted. "We're excited to further our strategic partnership with Audacy and to bring our market-leading sports betting and gaming entertainment content to millions of listeners nationwide across the entire BetQL Network platform," said Matt Prevost, Chief Revenue Officer, BetMGM.

10:00 EDT Nuvation Bio falls -7.8% - Nuvation Bio is down -7.8%, or -33c to $3.87.

10:00 EDT Costamare rises 6.0% - Costamare is up 6.0%, or 69c to $12.19.

10:00 EDT Genco Shipping rises 6.7% - Genco Shipping is up 6.7%, or $1.23 to $19.60.

09:47 EDT Spirit Airlines falls -5.3% - Spirit Airlines is down -5.3%, or -$1.29 to $23.23.

09:47 EDT Portland General Electric rises 6.0% - Portland General Electric is up 6.0%, or $2.82 to $49.82.

09:47 EDT American Realty Investors rises 6.7% - American Realty Investors is up 6.7%, or 93c to $14.80.

09:34 EDT SSR Mining trading halted, volatility trading pause

09:23 EDT Adial Pharmaceuticals announces database lock for ONWARD Phase 3 trial - Adial Pharmaceuticals announced database lock for the company's ONWARD Phase 3 clinical trial. The data sets have been transferred to the company's independent, external statistical consultants who have initiated the analysis of the data. Adial anticipates that it will provide top-line results in July 2022. "We are excited that data analysis has commenced and we look forward to reporting the topline results of ONWARD this July," said Dr. Bankole Johnson, Chief Medical Officer of Adial. "The primary endpoint of the ONWARD trial is reduction from baseline in the monthly number of heavy drinking days experienced by each patient during the last eight weeks of the 24-week treatment period. Secondary endpoints include reduction in total alcohol consumed and improvement as measured by the Patient Health Questionnaire-9, a widely accepted tool for assessment of depression. I am also pleased to reaffirm that no drug-related serious adverse events were reported during the trial." The ONWARD trial is a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel group, Phase 3 clinical study to evaluate the efficacy, safety and tolerability of AD04 in patients with Alcohol Use Disorder and selected polymorphisms in the serotonin transporter and receptor genes. Patients were genetically screened prior to enrollment in the ONWARD trial so that only genetically positive patients were enrolled. Approximately one-third of the screened patients tested genetically positive for the targeted genetics. ONWARD was conducted in 25 clinical sites in six countries in Scandinavia and Central and Eastern Europe (Sweden, Finland, Poland, Latvia, Bulgaria and Croatia). The principal investigator is Professor Hannu E.R. Alho, Emeritus Professor of Addiction Medicine at the University of Helsinki. The ONWARD trial is expected to serve as a basis for approval of AD04 for the treatment of Alcohol Use Disorder in patients identified as having the targeted genetics.

09:11 EDT Seanergy Maritime gets listing approval and ex-distribution date for spin-off - Seanergy Maritime Holdings announced that the application of United Maritime Corporation to list its common shares on the Nasdaq Capital Market has been approved. In addition, the registration statement on Form 20-F filed by United in connection with its spin-off from Seanergy has been declared effective by the U.S. Securities and Exchange Commission .Through United, Seanergy intends to effect a spin-off of the Company's oldest Capesize vessel, the M/V Gloriuship. United is expected to adopt a diversified business model, with investments across various maritime sectors. Seanergy shareholders do not need to take any action to receive United shares to which they are entitled, and do not need to pay any consideration or surrender or exchange Seanergy common shares. Seanergy common shareholders will receive one United common share for every 118 Seanergy common shares held at the close of business on June 28 , the record date for the distribution which coincides with the previously-announced record date for Seanergy's cash dividend of $0.025 per share for the first quarter of 2022. The distribution of United common shares is expected to be made on or around July 5, 2022. United common shares are expected to commence trading on a standalone basis on the Nasdaq Capital Market on the first trading day after the date of distribution, under the ticker "USEA". Nasdaq has established an ex-distribution date for the distribution of United common shares of June 27 . Beginning on that date, Seanergy shares will trade without an entitlement by the purchaser of such shares to United common shares distributed in connection with the spin-off. A "when-issued" trading market in United common shares will not be established, and United common shares will not begin trading on a standalone basis until the trading day following the date of distribution. Fractional common shares of United will not be distributed. Instead, the distribution agent will aggregate fractional common shares into whole shares, sell such whole shares in the open market at prevailing rates promptly after United's common shares commence trading on the Nasdaq Capital Market, and distribute the net cash proceeds from the sales pro rata to each holder who would otherwise have been entitled to receive fractional common shares in the distribution.

09:10 EDT Cepton, Koito Manufacturing announce intention to expand collaboration - Cepton (CPTN) and Koito Manufacturing (KOTMY) jointly announced their intention to expand their existing collaboration efforts to include select future Cepton lidar products and go-to-market activities. Detailed commercial terms are under discussion. Cepton and Koito's automotive supply partnership began in 2017. Since then, Cepton and Koito have worked together to execute the series production program and have recently shipped D samples to the OEM customer. Cepton and Koito intend to enter into a new agreement that will expand the scope of the companies' automotive development efforts. "In the past five years, our team has successfully collaborated with Koito to commercialize and scale the manufacturing of Cepton's lidar technology. Expanded collaboration will further strengthen the Koito-Cepton partnership and better positions both companies to address the opportunities in the automotive and non-automotive markets. I am honored and excited to deepen our relationship for the long run," said Jun Pei, Cepton's Co-Founder and CEO.

09:07 EDT Ingevity appoints Christine Stunyo as chief human resources officer - Ingevity (NGVT) announced it has named Christine Stunyo, formerly with Host Hotels & Resorts (HST), as chief human resources officer. In this role, Stunyo will be responsible for leading the company's global Human Resources function, including organization development, integrated talent management, leadership development and culture. She assumes the new role effective June 27, 2022.

09:06 EDT Limbach Holding exoands technology focus, appoints Ruci to CIO - Limbach announced the appointment of Christos Ruci as Chief Information Officer, CIO. Ruci was hired as VP of Technology to help organize and centralize the company's sue of technology internally in 2020. In his new role, Ruci will continue to report to Chief Financial Officer, Jayme Brooks.

09:04 EDT Brinker, Grubhub to bring Chili's, It's Just Wings to Grubhub marketplace - Grubhub, a U.S. food-ordering and delivery marketplace owned by Just Eat Takeaway.com (TKAYY), and Brinker International (EAT), announced a partnership to bring the Chili's Grill & Bar, It's Just Wings and Maggiano's Little Italy brands to Grubhub. More than 2,500 locations will be available on the Grubhub Marketplace in the coming weeks.

09:01 EDT AeroClean announces $15M private placement - AeroClean Technologies announced that it has entered into a securities purchase agreement with a single institutional investor for the purchase of 1,500,000 shares of its common stock and warrants to purchase up to an aggregate of 1,500,000 shares of common stock in a private placement. The purchase price for one share of common stock and a warrant to purchase one share of common stock is $10.00. The warrants have an exercise price of $11.00 per share. Warrants with respect to 1.26 million shares will become exercisable on the earlier of the effective date of a registration statement related to the transaction or the 90th day following the closing. The remainder of the warrants will become exercisable following shareholder approval of the transaction. The warrants will expire five years from the initial exercise date. The gross proceeds from the private placement are expected to be $15.0 million. The private placement is expected to close on or about June 29, 2022, subject to the satisfaction of customary closing conditions.

08:51 EDT Spire Global added to membership of Russell 3000 Index - Spire Global has been added as a member of the broad-market Russell 3000 Index, effective after the US market opens on June 27, as part of the 2022 Russell indexes reconstitution. Membership in the Russell 3000 Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000 Index or small-cap Russell 2000 Index as well as the appropriate growth and value style indexes. "We are honored to be included in the Russell 3000," said Peter Platzer, Spire's CEO. "This is a milestone event for the company and for our talented team who got us where we are today."

08:43 EDT Occidental Petroleum Manulife in lease pact for a carbon capture project in LA - 1PointFive, a subsidiary of Occidental's OXY(OXY) Low Carbon Ventures OLCV business, and Manulife Investment Management (MFC) announced that OLCV and Manulife entered into a lease agreement for approximately 27,000 acres of timberland in Western Louisiana. The agreement provides 1PointFive with access to subsurface pore space and surface rights to develop and operate a carbon sequestration hub, with access to permanently store industrial carbon emissions. Two Class VI injection permits, required by the EPA for geologic sequestration, have already been filed for the site. The lease agreement is a pivotal step in 1PointFive's strategic vision to develop carbon capture and sequestration hubs, some of which are expected to be anchored by Direct Air Capture DAC facilities..."We are excited to join with Manulife and lease the acreage to develop a hub that will provide sequestration infrastructure and services for industrial emitters and 1PointFive's future DAC facilities," said Dr. Doug Conquest, Vice President, OLCV. "This agreement strengthens our CCUS position and advances commercial-scale decarbonization solutions in line with Oxy's net-zero goals." 1PointFive and Manulife Investment Management are also exploring other locations and projects throughout the region and country with the potential to add additional acreage for carbon removal and sequestration. 1PointFive adheres to U.S. Environmental Protection Agency standards for monitoring, reporting and verifying the amount, safety and permanence of CO2 stored through secure geologic sequestration. The company and its affiliates hold three EPA-approved MRV plans for geologic sequestration. 1PointFive will apply this expertise toward the safe design and operation of the project.

08:42 EDT Compass Diversified joins Russell 2000, 3000 Indexes - Compass Diversified announced that it has been added to the Russell 2000 and 3000 Indexes at the conclusion of the 2022 Russell indexes annual reconstitution, effective after the US stock market opens today.

08:39 EDT UiPath to reduce about 5% of company's global workforce under restructuring - In a regulatory filing, UiPath disclosed that on June 24, the board of directors of the company approved restructuring actions to manage its operating expenses. These actions are expected to include an overall reduction of approximately 5% of the company's global workforce of approximately 4,200 as of April 30, 2022, with most of these reductions expected to occur by the end of the second fiscal quarter 2023. "Worldwide, we expect the workforce reductions to comply with applicable laws including consultation requirements. This workforce reduction is aimed at simplifying our go-to-market approach starting with an alignment that we believe will result in better market segmentation, higher sales productivity, and best-in-class customer experience and outcomes. The company estimates it will incur approximately $15 million in restructuring expenses, predominantly related to employee severance and compensation benefits, as well as contractual charges, consisting of lease termination and other related costs. We expect related charges to be recognized by the end of fiscal year 2023. The charges that the company expects to incur are subject to a number of assumptions, and actual expenses may differ materially from the estimates disclosed above," UiPath stated.

08:38 EDT Aerojet Rocketdyne CEO recommends shareholders vote for Independent Slate - The company states: "Eileen Drake, the CEO of Aerojet Rocketdyne, and the other members of the Committee For Aerojet Rocketdyne Shareholders and Value Maximization remind Aerojet Rocketdyne shareholders that the special meeting of shareholders for the purpose of electing a new slate of directors will be held on June 30, 2022. The Committee recommends that shareholders vote "FOR" the Independent Slate on the WHITE proxy card prior to the special meeting, in accordance with the previously-announced recommendations of independent proxy advisory firms Institutional Shareholder Services and Glass Lewis. A few of the many compelling factors cited by ISS in its report recommending shareholders vote FOR Ms. Drake and the Independent Slate include: 'Lichtenstein is responsible for the organizational rot that enabled this contest. His reinterpretation of the historical record is not at all believable, and has only damaged his case - although individual elements of performance and specific developments are challenging to parse, he cannot disclaim accountability for AJRD's overall state of affairs at any point in the recent past.' 'It is telling that not a single incumbent director without a business or personal link came to his support.' 'Issues with confidence and trust are particularly concerning in this case, seeing that Lichtenstein has historically been averse to providing shareholders with information'."

08:36 EDT Barnes & Noble Education renews cooperation agreement with Outerbridge - Barnes & Noble Education announced that it has renewed its cooperation agreement with Outerbridge Capital Management, which currently owns approximately 9.9% of the Company's outstanding shares. As part of the agreement, the Company has agreed to nominate Rory Wallace, Chief Investment Officer of Outerbridge, to election to the Company's Board of Directors at the 2022 Annual Meeting of Stockholders. The Company also announced that it will separate the Chairman and CEO roles, effective immediately. Vice Admiral John Ryan, the Company's current lead independent director, has been appointed as Chairman of the Board. "We look forward to welcoming Rory to our Board as an independent director," said John Ryan, Chairman of the Board. "The Board has gotten to know Rory well over the last several years and appreciate our collaborative relationship with Outerbridge as we continue to deliver value for BNED shareholders. We look forward to benefitting from his insights as we execute on our strategic plan, including growing course material sales through our inclusive access offerings, expanding our general merchandise business through our partnership with Fanatics and Lids and scaling our digital business as we drive earnings growth and shareholder returns." Under the terms of the renewed cooperation agreement, Wallace will be the sole Outerbridge nominee to stand for election to the Company's Board at the Annual Meeting and will serve on the Audit and Compensation Committees. The full agreement between BNED and Outerbridge will be filed in a Form 8-K with the U.S. Securities and Exchange Commission.

08:36 EDT PFSweb added to Russell 3000 Index - PFSweb will join the broad-market Russell 3000 Index at the conclusion of the 2022 Russell indexes annual reconstitution, effective after the US market opens on June 27.

08:34 EDT LM Funding announces agreement with multistate data hosting company - LM Funding America announced that it has entered into a hosting and services agreement with a multi-state data hosting company to host up to 4,200 of LMFA's S19J Pro Antminer Machines. The Bitmain S19J Pro Antminer Machine is a high efficiency, high hash rate machine for Secure Hashing Algorithm 256 mining that generates an average hash rate of 100 TH/s and has an average power consumption 3,000 kWh. LMFA anticipates that once all 4,200 machines are operational at the new facility, LMFA will have a total capacity of approximately 420 petahash capable of generating approximately 53 Bitcoin per month based on difficulty rates.1 LMFA expects all of its 5,000 newly purchased miners, including 800 miners not being hosted by the new vendor, will be operational by the fourth quarter of 2022, potentially generating a total of 504 petahash.

08:34 EDT Cenntro Electric added to Russell 2000, Russell 3000, Russell Microcap Indexes - Cenntro Electric Group announced that it has been added the Russell 2000, Russell 3000 and Russell Microcap Indexes effective after the market close on June 24, 2022 as part of FTSE Russell's annual reconstitution. "Cenntro's presence in the Russell 2000 and Russell 3000 Indexes is another important milestone that is a result of the considerable growth over the past year," said Peter Wang, Chairman and Chief Executive Officer of Cenntro Electric Group Limited.

08:33 EDT Casey's General Stores appoints Donthi to board of directors - Casey's General Stores (CASY) announced the appointment of Sri Donthi to its Board of Directors, bringing the number of directors from ten to eleven. Donthi currently serves as Executive Vice President and Chief Technology Officer at Advance Auto Parts (AAP).

08:33 EDT Thor Industries upsizes share repurchase authorization to $600M - THOR Industries announced that on June 24, 2022, the Board of Directors of THOR Industries reaffirmed its authorization to company management to utilize up to $250M to purchase shares of the company's common stock through December 21, 2024, with $151,678,891.47 remaining on the authorization as of June 24, 2022 and authorized company management to utilize up to an additional $448,321,168.53 to purchase shares of the company's common stock through July 31, 2025, bringing the total authorization to $600M and extending the duration of the program by approximately seven months.

08:32 EDT Sellas Life Sciences provides clinical update for GFH009 ongoing Phase 1 trial - SELLAS Life Sciences Group provided a clinical update on the ongoing Phase 1 dose-escalating clinical trial of GFH009, its novel and highly selective CDK9 inhibitor, in advanced relapsed and refractory lymphoma and acute myeloid leukemia. In the AML group, patients treated at the 22.5 mg dose level experienced no dose limiting toxicities, including no grade 3/4 neutropenias. The AML group has entered the last planned dose level of 30 mg. As previously reported, significant anti-leukemic effects have been observed in AML patients treated sufficiently long enough to assess efficacy at previous dose levels. In the lymphoma group, the 15 mg dose level cohort has completed enrollment. Safety assessments for this cohort are currently underway. In the previous 9 mg dose level cohort, one patient, with peripheral T-cell lymphoma, an aggressive type of lymphoma that develops from mature-stage T-cells and natural killer cells who was refractory to three prior lines of therapy, demonstrated a partial response as seen on a computerized tomography scan. "We continue to see positive results in our clinical efforts for GFH009, especially in assessing the safety in patients with lymphoma and AML," said Dragan Cicic, MD, Senior Vice President, Clinical Development of SELLAS. "The clinical process for safety is to determine the highest dose level patients can tolerate without experiencing adverse events or side effects. Not only does GFH009 appear to be safe at the dose levels studied to date, but we have also observed efficacy in lower dose levels. These results are encouraging as we continue to increase dose levels and assess accordingly."

08:30 EDT Universal Technical rejoins Russell 3000 Index - Universal Technical Institute has re-joined the broad-market Russell 3000 Index at the conclusion of the 2022 Russell indexes annual reconstitution, effective after the US market opens today.

08:28 EDT Hillstream BioPharma announces collaboration with Sapien Biosciences - Hillstream BioPharma announced a collaboration with Sapien Biosciences to evaluate the synergy of HSB-1216 with immune checkpoint inhibitors. "We are initiating studies, in collaboration with Sapien Biosciences, to determine the synergy between HSB-1216, our ferroptosis inducer and nivolumab, an anti-PD1 antibody," said Randy Milby, Hillstream's CEO. "In addition, we will also study the potential synergistic effects of HSB-1216 with the recently approved Bristol Myers Squibb drug Opdualag, a fixed dose combination of an anti-PD1 MAb + anti-LAG3 MAb, to demonstrate that targeting a ferroptosis-associated metabolism in tumors may improve the efficacy of cancer immunotherapy." "We are excited to extend our collaboration with Hillstream Biopharma to evaluate potential synergy between their HSB-1216 molecule and ICIs using our expertise in establishing patient tissue-derived cell models in oncology, immunology and Immune-oncology," said Dr. Jugnu Jain, CEO, Sapien Biosciences. "Previously, Sapien demonstrated potent anti-cancer activity of HSB-1216 in primary triple negative breast cancer cells which were presented at AACR 2020."

08:23 EDT Bio-Rad publishes corporate sustainability report - Bio-Rad Laboratories released its inaugural corporate sustainability report. The report is based on an assessment Bio-Rad conducted in 2021 to identify the highest priority topics for sustainability and to set targets for improvement. Bio-Rad's top sustainability focus areas include carbon footprint, operational energy, diversity and inclusion, sustainable packaging, and ethics and anti-corruption measures. These areas comprise the key elements of Bio-Rad's sustainability strategy and include the following long-term goals the company aims to achieve by 2030: reducing Scope 1 and 2 carbon emissions by 46%; purchasing renewable electricity for 100% of Bio-Rad's U.S. facilities; increasing the proportion of women in the company's U.S. leadership roles to 45%; ensuring that underrepresented employees make up 60% of Bio-Rad's U.S. workforce; reducing the use of non-recyclable packaging materials by 25%; achieving recognition as one of the most ethical companies in the world

08:20 EDT TPG appoints Bright as new independent director - TPG (TPG) announced that Gunther Bright has joined its Board of Directors as an independent director, effective July 1, 2022. Bright brings nearly 30 years of leadership experience at American Express (AXP), where he currently serves as Executive Vice President and General Manager of Global and U.S. Large Enterprises, Global Commercial Services.

08:19 EDT Home Depot adopts HPE GreenLake for Aruba Networking, Aruba ESP - Aruba, a Hewlett Packard Enterprise company (HPE), announced that The Home Depot (HD) has selected Aruba ESP delivered via HPE GreenLake for Aruba networking, to power advanced customer and associate experiences across its U.S. stores. The Home Depot has expanded its partnership with Aruba to architect "a solid network foundation that provides speed, scale, and flexibility. The HPE GreenLake for Aruba network as a service offering provides a compelling solution with agility and flexibility for The Home Depot," the company said.

08:17 EDT Cornerstone Pharmaceuticals to present pancreatic cancer data on CPI-613 at ESMO - The company states: "Cornerstone Pharmaceuticals announced that data on its lead compound CPI-613 in combination with gemcitabine and nab-paclitaxel in patients with locally advanced or metastatic pancreatic cancer will be presented at the European Society of Medical Oncology World Congress on Gastrointestinal Cancer 2022, taking place June 29 through July 2, 2022 in Barcelona, Spain." Angela Alistar, M.D., Medical Director of Gastrointestinal Medical Oncology at Atlantic Health System in New Jersey and principal investigator of the study says: "The results demonstrate that treatment with devimistat is feasible, well tolerated and potentially clinically synergistic with chemotherapy for patients with pancreatic adenocarcinoma. With each milestone, we're one step closer to delivering potential new treatment options."

08:15 EDT Alaunos Therapeutics, NCI expand CRADA to 2025 - Alaunos Therapeutics announced that the company has extended its Cooperative Research and Development Agreement with the National Cancer Institute, an institute of the National Institutes of Health, using the Alaunos Sleeping Beauty technology through January 2025. Under the terms of the CRADA, the NCI will work to generate proof of concept utilizing the Company's proprietary non-viral Sleeping Beauty technology for personalized TCR-T cell therapy. In this setting, T-cell receptors that react to the patient's tumor will be identified from the patient and used to generate a TCR-T cell therapy. This approach could potentially apply to a wide range of solid tumor cancer patients. Alaunos believes that the non-viral Sleeping Beauty technology could rapidly and cost effectively produce safe and potent TCR-T cell therapies without the complexity of gene editing or viral approaches. Research conducted under the CRADA will be led by Steven A. Rosenberg, M.D., Ph.D., Chief of the Surgery Branch at the NCI's Center for Cancer Research.

08:14 EDT Otsuka, Lundbeck announce results from Phase 3 trial of brexpiprazole - Otsuka Pharmaceutical and H. Lundbeck announce positive results of the Phase 3 clinical trial of brexpiprazole in the treatment of agitation in patients with Alzheimer's dementia. The analysis concluded that there is a statistically significant difference in the mean change from baseline to Week 12 in the Cohen-Mansfield Agitation Inventory, CMAI, total score between brexpiprazole and placebo. Full study results are not yet available. Further prespecified and exploratory analyses of the data set will be conducted to determine the full potential of brexpiprazole in the treatment of agitation in patients with Alzheimer's dementia. Based on this outcome Otsuka and Lundbeck are planning a regulatory filing to the U. S. Food and Drug Administration later in 2022. The Supplemental New Drug Application will be comprised of this study as well as two earlier trials.1 In February 2016, the FDA granted fast track designation for brexpiprazole for treatment of agitation in patients with Alzheimer's dementia.

08:13 EDT Daxor announces cooperative research and development Phase II agreement - Daxor Corporation announced that it has signed a Cooperative Research and Development Agreement with The Uniformed Services University, a medical school affiliated with all military branches of the United States, and The Henry M. Jackson Foundation for the Advancement of Military Medicine under the leadership of David Burmeister, PhD, Department of Medicine, USU and Brandon W. Popper, MD FACS, Department of Surgery, USU. In collaboration with USU and a grant received from AFWERX, a Technology Directorate of the Air Force Research Laboratory and the innovation arm of the Department Air Force, Daxor is developing an updated diagnostic device and tracer system to replace the current I-131 nuclear tracer used in the BVA-100 Blood Volume Analyzer.

08:13 EDT Greywood Investments issues letter to Enthusiast Gaming shareholders - Greywood Investments, LLC, which, together with its associates and affiliates is the largest shareholder of Enthusiast Gaming Holdings Inc., advised shareholders that it has issued a letter to shareholders and Proxy Circular and related voting materials in connection with Enthusiast's annual general meeting which is scheduled to be held on July 19, 2022. "The Concerned Shareholders outlined several issues they believe are impeding the Company from reaching its full potential, including poor corporate governance, an unfair compensation structure and an operating culture that has led to the departure of many of the founders of the businesses acquired by Enthusiast and a real risk that the Company will not be able to retain key employees. After having its concerns ignored by an entrenched Board, the Concerned Shareholders acted. They have nominated an outstanding slate of director nominees, who have the requisite industry and leadership experience to address the poor and damaging culture, governance and performance failures under the current Enthusiast Board and CEO. This has been met with overwhelming support from current and former Enthusiast industry visionaries and leaders who have pledged their support to the campaign to Upgrade Enthusiast. Shareholders now have the opportunity to ensure that their Company will retain its talent and reach the multi-billion-dollar valuation that the Concerned Shareholders and other long-term Enthusiast investors believe is within reach. To ensure that the Company's best days are ahead, the Concerned Shareholders recommend that fellow shareholders vote using only the GOLD form of proxy FOR six exceptional director nominees to Upgrade Enthusiast - Jon Dakss, Raphael Danon, David Goldhill, Mark Klein, Janny Lee and Dan Petrozzo. As Enthusiast's management has put forward nine director nominees, the Concerned Shareholders also recommend that fellow shareholders vote FOR three director nominees from management's slate - Seth Berger, Alan Friedman, and Angela Ruggiero. The Concerned Shareholders also sought to have Shinggo Lu, the founder and general manager of U.GG, nominated to stand for election to the Board on its slate of nominees, though were blocked by the Company after Mr. Lu expressed support for our campaign. The Concerned Shareholders' director nominees intend to appoint Mr. Lu to Enthusiast's Board, should they be elected at the upcoming shareholder meeting."

08:11 EDT Energy Vault joins the Russell 2000 Index - Energy Vault Holdings announced that they have joined the Russell 2000 Index following the conclusion of the 2022 Russell indexes annual reconstitution, effective today, Monday, June 27, 2022 at market open. "We are excited to be added to the Russell family of indices," said Robert Piconi, Chairman, Co-Founder and CEO of Energy Vault. "Our inclusion in the Russell 2000 marks another important milestone for Energy Vault during this transformative year for the company, giving us a greater opportunity to increase our exposure to the broader investment community, and expand awareness for our mission of accelerating the decarbonization of our planet."

08:10 EDT Avaya announces $600M financing - Avaya Holdings announced $600M in aggregate financing commitments. The Company priced $350M in aggregate principal amount of new Senior Secured Term Loans and entered into agreements for the private placement of $250M in aggregate principal amount of Exchangeable Senior Secured Notes, all due in 2027. The combined principal amount of the offerings was raised from the previously announced offering size of $500M due to increased demand. The closing of each transaction is expected to occur substantially concurrently and is subject to market and customary closing conditions. "We are pleased with the successful execution of this financing," said Kieran McGrath, Chief Financial Officer, Avaya. "This funding supports and accelerates our business model transformation and addresses our convertible notes maturing in June of next year."

08:09 EDT Canadian National to invest $30M in Tennessee in 2022 - CN announced plans to invest approximately $30M in Tennessee in 2022. This includes investments in technology, rolling stock units and company-wide decarbonization initiatives, as well as network improvements. These investments will power sustainable growth and ensure the continued safe movement of goods in Tennessee and everywhere on CN's transcontinental network.

08:08 EDT US Foods opens distribution facility in Sacramento, California - US Foods announced the opening of the company's 70th distribution facility, located in Sacramento, California. The new 355,000-square-foot state-of-the art distribution facility and customer engagement training center reflects a variety of sustainable building and fleet initiatives undertaken by US Foods, making it the most environmentally sustainable distribution facility the company has built to date. "Our state-of-the-art facility in Sacramento enables US Foods to more efficiently serve independent restaurants and foodservice operators across Northern California due to its proximity to our growing customer base and the energy-efficient attributes of the building and fleet reflect our commitment to sustainability," said Dan Geissbuhler, US Foods area president. "Sacramento's dynamic economy continues to foster business growth and expansion opportunities, and we're eager to showcase the many benefits the facility will bring to our customers as we help them Make It."

08:07 EDT Analog Devices appoints Andonian to board of directors - Analog Devices announced that its Board of Directors has appointed Andre Andonian as an independent director effective as of June 27, 2022. Andonian is the Chief Executive Officer of Andonian Advisory, a consulting and advisory firm that he founded that provides board and executive level advisory services to both public and private companies.

08:07 EDT Kaival: CEO Patel to transition to Chief Science and Regulatory Officer - Kaival Brands Innovations Group (KAVL) announced that its CEO and founder, Nirajkumar Patel, will transition to Chief Science and Regulatory Officer. Eric Mosser, the Company's current COO, will become President and remain COO. Mosser will serve as the Company's principal executive officer for purposes of its filings with the Securities and Exchange Commission. Patel will remain on the Board of Directors for Kaival Brands. The management changes follow the Company's recently announced international licensing agreement with a Philip Morris International (PM) affiliate, Philip Morris Products S.A. on June 13, 2022. The International Agreement grants to PMPSA a license of certain intellectual property rights relating to Bidi Vapor's premium electronic nicotine delivery system device, the BIDI Stick, in the U.S., as well as potentially newly developed devices, to permit PMPSA to manufacture, promote, sell, and distribute such ENDS device and newly developed devices, in international markets outside of the U.S. The transition will allow Mr. Patel to focus on developing new products and expanding the Bidi Vapor product portfolio, which is directly related to the new agreement with PMPSA, and allow Mosser to focus on expanding sales distribution channels and increasing the revenues and profits of Kaival Brand.

08:05 EDT Curaleaf, Fab 5 Freddy expand B NOBLE cannabis brand to New Jersey - B Noble Inc. and Curaleaf Holdings announced the expansion of its B NOBLE product partnership in New Jersey. The brand's 2-pack pre-rolls are now available at Curaleaf's locations in Bellmawr and Edgewater Park, as well as medical and adult-use dispensaries across the state.

08:04 EDT Cybin receives FDA IND clearance for Phase 1/2a trial evaluating CYB003 - Cybin announced that it has received a "may proceed letter" and Investigational New Drug Application, IND, clearance from the U.S. Food and Drug Administration, FDA, for its Phase 1/2a first-in-human clinical trial evaluating CYB003. CYB003 is a proprietary deuterated psilocybin analog that is being developed for the potential treatment of major depressive disorder, MDD. The Company will begin recruiting patients immediately and expects to provide an interim pharmacokinetic and safety data readout in Q4 2022. "We are extremely pleased to advance CYB003 into clinical development so quickly. Our team has worked diligently to achieve this major regulatory milestone and we look forward to collaborating with Clinilabs, our drug development partner, to accelerate this program," said Doug Drysdale, Chief Executive Officer of Cybin. "This Phase 1/2a trial represents the first time that a psilocybin analog will be evaluated for the treatment of MDD and is the key next step toward our ultimate goal of providing a new and effective treatment for people suffering with mental health conditions."

08:03 EDT CECO Environmental completes acquisiton of Western Air Ducts - CECO Environmental announced it has completed the acquisition of industrial air quality consultancy and engineering firm, Western Air Ducts Ltd, and its patented air control system Inteliair. Effective immediately, both brands will be folded into CECO's industrial air platform.

08:02 EDT UpHealth announces delay of annual meeting - UpHealth issued the following statement regarding the Delaware Court of Chancery's ruling in advance of the Company's Annual Stockholders Meeting: "We welcome last week's Delaware Court of Chancery ruling, which delays the current Annual Meeting to a later date to allow the Court to review all relevant materials and proceed with the trial on the limited issue of the change in quorum announced on May 31, 2022. We note that, in its ruling preliminarily enjoining the Annual Meeting, the Court stated that it "do[es] not doubt the defendants' good faith. We believe the actions by the plaintiffs, Dr. Chirinjeev Kathuria and Jeffery Bray, and by their group of aligned supporters, including Dr. Mariya Pylypiv, are a self-serving attempt to wield outsized influence over the future direction of UpHealth by inhibiting the Company's proper governance. We note that plaintiff, Mr. Bray, is a creditor of UpHealth and has been seeking to be paid more than $17 million, and that co-plaintiff Dr. Kathuria appears to be trying to gain control of UpHealth without paying a premium to shareholders. Dr. Kathuria and Dr. Pylypiv, among others, organized the Conflicted Group, and it further appears, failed to make appropriate public disclosures of their intentions. The plaintiffs sought an order affirming Dr. Kathuria's unilateral right as Co-Chairman of the Board to call a Special Meeting of Shareholders to further his own agenda. Noting that there was no "pattern of behavior ... that one co-chair can unilaterally override the other," the Court determined that the plaintiffs were not reasonably likely to prevail on this point. To ensure the proper functioning of the Board, as previously announced, the Board has now appointed a single Non-Executive Chairman and removed Dr. Kathuria from the role of Co-Chairman. The Company is confident that the defendant directors will demonstrate at trial the propriety of all of their actions, including in modifying the quorum requirements for the Company's Annual Meeting to enfranchise all shareholders. The defendant directors are committed to continuing to act vigorously to protect the interests of all shareholders. Furthermore, the Company reserves all of its rights to pursue claims against any member of the Conflicted Group for not acting in the best interests of the Company, inappropriate disclosure of confidential materials, and violation of their fiduciary duties as Directors and as Executives in the company. Despite the Conflicted Group's repeated attempts to discourage voting at the Annual Meeting, more than 75% of the shares that were not owned by members of the Conflicted Group had submitted proxies as of the close of business on Friday, June 24. The Company sincerely thanks the shareholders for demonstrating overwhelming support for the Board's recommendations. The Company is confident that in due course UpHealth shareholders will have the opportunity to meaningfully influence the direction of the Company and that the voice of all shareholders will be heard."

08:01 EDT Nikola urges shareholders to vote for Proposal 2 - Nikola Corporation urges all stockholders to vote now FOR Proposal 2 before the Annual Meeting on June 30. Stockholders must vote before the deadline at 11:59 p.m. Eastern Time on June 29, 2022, to ensure their votes are counted. "Approving Proposal 2 is very important. Nikola has 600 million common shares authorized. The combination of fully diluted shares, including shares outstanding and options, restricted stock units and warrants, and reserved/unissued shares from Nikola's equity line of credit and convertible notes means the Company has approximately 567 million fully diluted and reserved/unissued shares, as of June 8, 2022. This leaves Nikola with approximately 33 million shares available for other purposes. That is why we are urging all stockholders to vote NOW FOR Proposal 2, which would allow Nikola to increase the authorized number of shares of the Company's common stock to 800 million, providing flexibility to support the growth of the business."

07:59 EDT Imperial Oil receives acceptance from TSX to purchase up to 5% of shares - Imperial Oil (IMO) announced that it has received final acceptance from the Toronto Stock Exchange, TSX, for a normal course issuer bid to repurchase up to five percent of its 636,676,182 outstanding common shares as of June 15, 2022, or a maximum of 31,833,809 shares during the next 12 months. This maximum will be reduced by the number of shares purchased from Exxon Mobil (XOM), Imperial's majority shareholder, as described below. The new one year program will begin on June 29, 2022, and will end should the company purchase the maximum allowable number of shares, or on June 28, 2023. Imperial has established an automatic share purchase plan with its designated broker to facilitate the purchase of common shares, both under the NCIB and concurrently from ExxonMobil, during times when Imperial would ordinarily not be permitted to purchase due to regulatory restrictions or self-imposed black-out periods. Before entering a black-out period, Imperial may, but is not required to, instruct the broker to make purchases under the NCIB based on parameters set by Imperial in accordance with the share purchase plan, TSX rules and applicable securities laws. The plan has been pre-cleared by the TSX and will be implemented effective June 29, 2022. All share purchases will be made through the Toronto Stock Exchange and through other designated exchanges and published markets in Canada. Shares purchased under the NCIB are cancelled and restored to the status of authorized but unissued shares. The acceptance marks the continuation of Imperial's most recent normal course share repurchase program that was completed on January 31, 2022.

07:49 EDT Cronos Group announces partnership with Geocann - Cronos Group announced the launch of the first of what is expected to be a range of products, in partnership with Geocann, which will utilize the advanced VESIsorb delivery system. "We are committed to bringing breakthrough innovations to the market, providing consumers with differentiated and high-quality products," said Mike Gorenstein, Chairman, President and CEO, Cronos. "Working with Geocann's technology enables us to expand our product offering to bring consumers a fast-acting cannabinoid product with a quicker onset than previously available, along with improved efficacy, helping enhance and differentiate effect and experience." The first VESIsorb formulated product the companies have launched together are the CBD Gel Capsules by Lord Jones.

07:39 EDT Accenture to acquire XtremeEDA, terms not disclosed - Accenture "has entered into an agreement to acquire XtremeEDA, an Ottawa-based silicon design services leader. The company provides semiconductor engineering services for clients seeking custom silicon solutions used in consumer devices, cloud data centers, machine learning and artificial intelligence computational platforms to enable edge AI deployment. The terms of the acquisition were not disclosed."

07:38 EDT TG Therapeutics presents exploratory analyses from ublituximab in MS trial - TG Therapeutics announced data presentations highlighting data from pooled and post hoc analyses of the ULTIMATE I & II Phase 3 trials evaluating ublituximab in patients with relapsing forms of multiple sclerosis presented at the 8th Congress of the European Academy of Neurology . Links to the presentations are included below. Michael S. Weiss, Chairman and Chief Executive Officer of TG Therapeutics stated, "We are encouraged by the findings from these additional exploratory analyses of the ULTIMATE I & II Phase 3 trials, which reinforces our belief in the potential of ublituximab in the treatment of relapsing forms of multiple sclerosis. As a company, our primary focus remains on obtaining FDA approval of ublituximab by December 28 , the PDUFA goal data." ULTIMATE I and ULTIMATE II are two independent Phase 3, randomized, double-blinded, active-controlled, global, multi-center studies evaluating the efficacy and safety/tolerability of ublituximab in subjects with relapsing forms of Multiple Sclerosis . The ULTIMATE I & II trials enrolled a total of 1,094 patients with RMS across 10 countries. These trials were led by Lawrence Steinman, MD, Zimmermann Professor of Neurology & Neurological Sciences, and Pediatrics at Stanford University and were conducted under a Special Protocol Assessment agreement with the U.S. Food and Drug Administration . As previously announced, both studies met their primary endpoint with ublituximab treatment demonstrating a statistically significant reduction in annualized relapse rate (ARR) compared to teriflunomide over a 96-week period.

07:35 EDT BridgeBio announces data for for BBP-711 to treat recurrent kidney stone formers - BridgeBio Pharma announced positive Phase 1 data for BBP-711 in healthy volunteers, supporting the development of the investigational therapy for patients with primary hyperoxaluria type 1 and recurrent kidney stone formers. The data were shared in a feature oral presentation at European Society for Pediatric Nephrology 2022, taking place in Ljubljana, Slovenia. BBP-711 is an orally-administered small molecule inhibitor of glycolate oxidase that is being developed to treat conditions of excess oxalate. Overproduction of oxalate in hyperoxaluria, including PH1 and recurrent kidney stone formers with elevated oxalate, can lead to kidney stone formation, nephrocalcinosis and renal impairment. PH1 affects an estimated 5,000 patients in the United States and European Union, while recurrent stone formers are much more common, affecting an estimated 1.5 million individuals in the United States and European Union. "PH1 is a severe genetic condition with a high degree of morbidity, including kidney stones, calcification in the kidneys and deposition of calcium oxalate in many vital organs. Despite major advances in the field of hyperoxaluria, PH1 remains a disease with high unmet medical need in many parts of the world," said Scott Adler, M.D., chief medical officer and vice president of clinical development at Cantero Therapeutics, the BridgeBio affiliate developing BBP-711. "These data are encouraging for patients with PH1 as BBP-711 could become a novel oral therapy to prevent hyperoxaluria and its long-term consequences." BBP-711 was evaluated in a two-part, randomized, double-blinded, placebo-controlled, ascending dose Phase 1 study with 92 healthy volunteers. The Phase 1 data included: The pharmacokinetic parameters demonstrated that the drug was rapidly absorbed with a time to maximum concentration of ~2.5 hours and an elimination half-life of ~26 hours, supportive of once-daily dosing The results showed rapid and clinically meaningful pharmacodynamic increases in plasma glycolate of 10-15-fold above baseline levels, the highest response publicly reported to date of any GO-targeting agent tested in healthy volunteer PK-PD modeling of this data predicts that near-complete inhibition of GO can be sustained throughout the dosing period BBP-711 was well-tolerated with evaluated single doses 40 to 3,000 mgs and multiple doses of 75 to 1000 mgs. Treatment emergent adverse events were low in frequency and mild or moderate, with no changes in clinical laboratory measures, ECG, or vital signs observed Based on the data, BridgeBio intends to initiate a Phase 2/3 study in PH1. The study is expected to consist of two parts: Part A will include a dose-finding period to identify a well-tolerated therapeutic dose for Part B; Part B will be a randomized, placebo-controlled trial. Key secondary endpoints include absolute change from baseline in 24-hour UOx excretion corrected for body surface area and percentage of participants with 24-hour UOx below upper limit of normal . "PH1 is a severe and progressive genetic disease. It is often undiagnosed or misdiagnosed in infancy, childhood, adolescence and adulthood and can lead to intensive dialysis or kidney and liver transplantation," said Kim Hollander, executive director of the Oxalosis and Hyperoxaluria Foundation. "We are encouraged by the potential of an oral therapy for people living with this serious genetic condition. It provides hope to patients praying for a new treatment option, seeking to alleviate the burden of medical care management and achieve an improved quality of life." The Company also intends to launch a proof-of-concept Phase 2 study in adult recurrent kidney stone formers with elevated urinary oxalate excretion at the end of 2022, pending discussions with regulatory agencies. Additional studies are planned to address all patients with hyperoxaluria including patients less than six years of age and patients with impaired renal function.

07:33 EDT Holley added to membership of the small-cap Russell 2000 Index - Holley was added as a member of the US small-cap Russell 2000 Index, effective after the US market opens on June 27, as part of the 2022 Russell indexes reconstitution. Membership in the Russell 2000 Index, which remains in place for one year, is based on membership in the broad-market Russell 3000 Index. The stock also was automatically added to the appropriate growth and value indexes. "Following Holley's public listing last July, we are pleased to join the Russell Universe of Indexes less than a year after our public debut," commented Dominic Bardos, Chief Financial Officer of Holley. "The inclusion in these indexes is an excellent milestone for Holley, and we welcome the increased awareness and visibility of our company within the investment community."

07:32 EDT Foot Locker to divest team sales business

07:31 EDT Trump-linked SPAC Digital World reports receipt of grand jury subpoena - In a regulatory filing, Digital World Acquisition Corp. stated: "As previously disclosed in Digital World's Form 8-K filed on June 13, 2022, Digital World has been informed that it is the subject of an investigation pursuant to Section 8(e) of the Securities Act, with respect to the Registration Statement relating to its Business Combination. Digital World has also received several document requests and subpoenas from the SEC, seeking various documents and information regarding, among other things, Digital World's due diligence regarding TMTG, communications regarding and due diligence of potential targets other than TMTG, relationships between and among Digital World (and/or certain of Digital World's officers and directors) and other entities (including ARC Global Investments II LLC, Digital World's sponsor, and certain advisors, including Digital World's underwriter and financial advisor in its initial public offering). On June 16, 2022, Digital World became aware that a federal grand jury sitting in the Southern District of New York has issued subpoenas to each member of Digital World's board of directors; the subpoenas seek certain of the same documents demanded in the above-referenced SEC subpoenas, along with requests relating to Digital World's S-1 filings, communications with or about multiple individuals, and information regarding Rocket One Capital. Additionally, on June 24, 2022, Digital World received a grand jury subpoena with substantially similar requests. These subpoenas, and the underlying investigations by the Department of Justice and the SEC, can be expected to delay effectiveness of the Registration Statement, which could materially delay, materially impede, or prevent the consummation of the Business Combination." Previously, on June 14, Digital World Acquisition Corp had announced that it has been "tirelessly working towards consummating its proposed business combination with Trump Media & Technology Group Corp. and to afford Digital World stockholders, both large and small, the opportunity to participate in the process of the business combination."

07:28 EDT Stealth BioTherapeutics Corporation (ADS) trading halted, news pending

07:19 EDT Agrify enters New Zealand cannabis market with $1.625M Ora Pharm pact - Agrify announced it has signed a definitive agreement to supply Ora Pharm, a Waikato, New Zealand-based health and wellness company developing high-quality, sustainably-produced medicinal cannabis, with a full suite of end-to-end hardware and software products to be utilized at a 5,000-square-foot facility in Auckland, New Zealand. Under the terms of the Agreement, which has a base value of $1.625M, Ora Pharm, a licensed cultivator and distributor of medicinal cannabis, has committed to purchase 20 Vertical Farming Units VFUs that will be used to grow cannabis, as well as several cutting-edge extraction technologies including a C1D1 Extraction Pod, a C-15 Centrifuge Extraction System, and the CannaBeast 13 Thin Film Distillation System. In addition, Agrify will provide access to the fully integrated Agrify Insights seed to sale automation software for five years in exchange for monthly recurring SaaS fees. All of these cultivation and extraction solutions will form a robust ecosystem to give Ora Pharm complete and precise control over the full life cycle of its botanicals from new plants to finished products and should enable Ora Pharm to achieve new operational efficiencies and better overall results. With the rapid emergence and expansion of cannabis markets around the world, the global cannabis industry is on track to reach $35B this year and is projected to surpass $61B by 2026, according to BDSA. Located in the Asia-Pacific region, Ora Pharm is well positioned to easily serve a variety of attractive markets with high-quality cannabis products. The company currently has an Australian market presence and contracts to strategically expand into the United States, Europe, Asia, and its home country of New Zealand. Additionally, Ora Pharm has recently received a coveted grant from Callaghan Innovation to research cannabis cultivation inputs in New Zealand. By employing Agrify's solutions, Ora Pharm will gain new operational insight and data visibility to verify active ingredient levels. The partnership with Agrify also supports the continuation of Ora Pharm's broader mission to consistently deliver high-quality cannabis and manufactured finished products of major and minor cannabinoids.

07:15 EDT Frontier Group issues open letter to Spirit Airlines shareholders - Frontier Group (ULCC), parent company of Frontier Airlines, issued the following letter to Spirit Airlines' (SAVE) stockholders regarding Frontier's proposed merger with Spirit. "Dear Spirit Stockholders, We continue to be excited about the Spirit-Frontier combination, which will create a true nationwide ultra-low-fare airline... Our combination gives Spirit stockholders the opportunity to realize significant upside in excess of $50 per share, delivering superior value compared to JetBlue's proposal. The Frontier-Spirit transaction delivers significantly greater value to Spirit stockholders compared to the opportunistic cash offer from JetBlue, which creates a hard cap on value at $33.50 per share...The math is clear - even with modest growth assumptions based on current recovery trends - the Frontier-Spirit transaction can easily provide proforma value in excess of $50 per Spirit share, value that is far superior to what JetBlue offers... Leading proxy advisory firms support Frontier and Spirit transaction. ISS and Glass Lewis recognize the value of the Frontier-Spirit combination and have recommended that Spirit stockholders vote to approve the transaction... We have increased the reverse termination fee to $350 million, matching JetBlue's proposal and providing a portion in accelerated prepayment... A Spirit acquisition by JetBlue would lead to an antitrust dead end-a fact that no amount of JetBlue money, bluster or misdirection will change. JetBlue has thrown up a lot of smoke to have you believe that the regulatory risk of its proposal is identical to the Frontier-Spirit combination. That is not true, and requires you to ignore common sense and JetBlue's own admission about what it intends to do immediately upon acquiring and eliminating Spirit: remove seats and raise prices, both antitrust non-starters...Employees support the Frontier-Spirit combination. The Association of Flight Attendants, which represents over 4,600 flight attendants at Spirit and 2,900 flight attendants at Frontier, has publicly stated that it believes the Spirit-Frontier combination will significantly benefit employees of both airlines... Together, Frontier and Spirit will supercharge the ultra-low-cost carrier model to increase industry competition..."

07:13 EDT Aclaris Therapeutics appoints Gail Cawkwell, MD, PhD, as Chief Medical Officer - Aclaris Therapeutics,announced the appointment of Gail Cawkwell, MD, PhD, as Chief Medical Officer, effective today. "We are excited to welcome Dr. Cawkwell to Aclaris at this time as we are executing on a number of clinical programs," said Dr. Neal Walker, President and CEO of Aclaris. "Her leadership experience in pharmaceutical development as well as her clinical background will be extremely valuable in navigating the strategic direction of our drug development pipeline." Dr. Cawkwell is a pediatric rheumatologist and epidemiologist who brings over 20 years of pharmaceutical development and medical affairs experience in large and small companies, and across multiple disease areas. Most recently, she served as Senior Vice President, Medical Affairs, Safety & Pharmacovigilance at Intercept Pharmaceuticals, Inc. Prior to that, Dr. Cawkwell worked for Purdue Pharma L.P. most recently as Special Advisor to the Board of Directors, and Pfizer Inc., most recently as Vice President Medicine Team Lead for Pfizer's tofacitinib franchise. Dr. Cawkwell also previously served as a Clinical Instructor of Pediatrics at Columbia Presbyterian Health Center.

07:11 EDT Precision BioSciences announces closing of underwritten offering of stock - Precision BioSciences announced the closing of an underwritten offering of 35,971,224 shares of its common stock at an offering price of $1.39 per share, for total gross proceeds of approximately $50M, before deducting underwriting discounts and commissions and offering expenses payable by the Company. All of the shares of common stock were offered by the Company. The Company intends to use the net proceeds of the offering to help fund ongoing and planned research and development, and for working capital and general corporate purposes. The offering included new investors, including Great Point Partners, LLC, EcoR1 Capital, Heights Capital Management, Sphera Healthcare and Altium Capital, as well as participation from existing stockholders, including Cowen Healthcare Investments and Sio Capital Management. With the proceeds from this offering, the $25 million equity purchased by Novartis at $2.01 per share and the pending receipt of $50 million upfront cash payment from Novartis, Precision expects that existing cash and cash equivalents, expected operational receipts, and available credit will be sufficient to fund its operating expenses and capital expenditure to year end 2024.

07:10 EDT Canada Nickel announces assay results and confirms discovery at Reid Property - Canada Nickel Company announced today assay results at its Reid property, where two drill holes have been completed as part of its regional exploration program. Drilling was highlighted by hole REI21-02 which intersected 354 meters of 0.24% nickel and includes 15 meters of 0.39% nickel and 6 meters of 0.57% nickel. Mineralogy completed on samples from these holes confirmed that they contain the same heazlewoodite-pentlandite-awaruite minerals as Crawford. Mark Selby, Chair and Chief Executive Officer said, "We are very pleased with our drilling on the Reid target. The assay results from the second hole achieved expected grades over 354 metres and contains a core of higher grade mineralization of 15 metres of 0.39% nickel, and the first hole intersected a PGM zone similar to that at Crawford. We are continuing to drill Reid as we highlight the resource potential of this target with a larger geophysical footprint than our original Crawford discovery. Additionally, we are looking forward to the release of our updated resource estimate for Crawford expected to be released by July 6, 2022." Canada Nickel also announces that it has agreed to issue 100,000 common shares pursuant to the terms of an exploration agreement relating to the Company's Crawford Project and 34,200 common shares pursuant to the settlement of certain matters with a third party service provider. These issuances are subject to the prior approval of the TSX Venture Exchange. The common shares described in this news release will be subject to a statutory four-month hold period from the date of issuance under applicable securities laws.

07:08 EDT ADMA Biologics receives FDA approval for sixth plasma collection center - ADMA Biologics announced that it has received U.S. FDA approval for its sixth ADMA BioCenters plasma collection facility located in Myrtle Beach, South Carolina. This plasma collection facility commenced operations and initiated source plasma collection in the fourth quarter of 2021. With the approval announced today, this facility is now FDA-approved to collect and introduce into interstate commerce, human source plasma for further manufacturing in the U.S., the company said in a statement.

07:08 EDT EVgo, General Motors activate Plug and Charge across EVgo network - EVgo Inc. (EVGO) and General Motors (GM) announced the availability of Plug and Charge for all GM EVs with DC fast-charging capability on the EVgo network. Plug and Charge enables EVgo GM customers to start a fast-charging session in seconds without the need to open a mobile app or swipe an RFID or credit card, saving EV drivers time and helping to deliver a seamless and secure charging experience. "At its core, this latest iteration of the Autocharge technology is a customer convenience feature that can save drivers time by simplifying the fast-charging experience while maintaining a high level of security and protection," said Ivo Steklac, Chief Technology Officer at EVgo. "In collaboration with GM, EVgo continues to implement new technology across multiple hardware and software platforms to enhance the charging experience."

07:07 EDT Tonix Pharmaceuticals announces trial design of new TNX-1300 Phase 2 study - Tonix Pharmaceuticals Holding Corp announced the design of a new Phase 2 clinical trial of TNX-1300 for the treatment of cocaine intoxication. This new protocol has the potential to serve as a pivotal trial. TNX-1300 is a recombinant enzyme that efficiently degrades and metabolizes cocaine in cocaine users, as demonstrated in a prior Phase 2a randomized, double-blind, placebo-controlled clinical study, providing support of the use of TNX-1300 as a treatment for cocaine intoxication. The company plans to submit the new protocol to the U.S. Food and Drug Administration. A positive Phase 2a study of volunteer cocaine users in a controlled laboratory setting has been previously completed. TNX-1300 has been granted Breakthrough Therapy designation by the FDA. As a biologic and new molecular entity, TNX-1300 is eligible for 12 years of U.S. market exclusivity upon approval by the FDA, in addition to expected patent protection through 2029. The Phase 2 trial is a single-blind, open-label, placebo-controlled, randomized study comparing the safety of a single 200 mg dose of TNX-1300 to standard of care alone for the treatment of signs and symptoms of acute cocaine intoxication in approximately 60 emergency department patients presenting with cocaine intoxication. During the treatment period, subjects assigned to receive TNX-1300 will receive a single IV injection of TNX-1300 administered over 2 minutes or less; whereas subjects assigned to receive standard of care alone will receive a single IV saline injection over 2 minutes or less. Both groups will be observed according to the site's emergency department protocol. For both study arms, signs and symptoms of cocaine intoxication will be assessed at pre-determined time points after treatment (30 minutes and then at 60, 90, 120, 180, and 240 minutes). After randomization, blood samples will be drawn at specific time points. The primary endpoint of the study is reduction of systolic blood pressure associated with acute cocaine intoxication identified at study baseline comparing TNX-1300 and standard of care after 60 minutes. A variety of secondary endpoints will be measured, including reduction of circulating cocaine, cocaethylene and ecgonine methyl ester levels after at multiple post-baseline timepoints. Safety assessments will consist of incidence and severity of treatment-emergent adverse events, adverse events of special interest, 12-lead ECGs, and vital signs.

07:06 EDT Microvast joins Russell 3000 Index - Microvast announced that it has joined the broad-market Russell 3000 Index in connection with the 2022 Russell indexes annual reconstitution. "Inclusion in the Russell indexes marks an important milestone for Microvast as a publicly traded company," said Sascha Kelterborn, President of Microvast. "We also believe that inclusion in the Russell indexes will broaden awareness of Microvast within the institutional investor community and open up a new category of potential investors. We welcome the increased visibility as we continue our efforts to drive value for our shareholders."

07:04 EDT Primoris enter agreement to acquire PLH in all-cash transaction valued at $470M - Primoris Services announced that it has entered into a definitive merger agreement to acquire PLH Group in an all-cash transaction valued at $470M. Primoris, one of the top specialty contractors in the U.S., provides critical infrastructure services to the utility, renewables and other related energy markets. Strategic Advantages and Benefits: Nearly doubles Power Delivery business and increases the Company's Utilities segment to over 50 percent of pro forma revenue; Solidifies Power Delivery presence in the five fastest-growing states to create more turnkey opportunities; Accelerates the Company's ongoing portfolio transition towards higher-growth, higher-margin markets and recurring Master Service Agreement revenue "This acquisition aligns solidly with our strategic focus on higher-growth, higher-margin business segments," said Tom McCormick, President and Chief Executive Officer of Primoris. "It expands our footprint for Power Delivery services at a time when improvement and expansion of our domestic electric grid is driving massive capital investment in this market."

07:03 EDT Medtronic names Pfizer executive Lidia Fonseca as new director - Medtronic plc (MDT) announced that its Board of Directors appointed Lidia Fonseca, Executive Vice President, Chief Digital and Technology Officer at Pfizer (PFE), to the Board as an independent director, effective June 27, 2022. Fonseca will serve on the Compensation Committee and Science and Technology Committee of the Board.

07:01 EDT Nuvation Bio announces FDA partial hold for Phase 1 study of NUV-422 - Nuvation Bio announced the Food and Drug Administration, FDA, has placed a partial clinical hold on the Company's Phase 1 dose escalation study of NUV-422 in solid tumors, including high grade glioma, HR+/HER2- advanced breast cancer and metastatic castration resistant prostate cancer. The Company's Phase 1 trial began enrolling patients 19 months ago in December 2020 and, in recent months, was exploring higher doses to define a maximum tolerated dose. Following the emergence of uveitis, a form of inflammation in the eye, in certain patients receiving NUV-422, the Company proactively paused enrollment of new patients in order to further assess these adverse events with investigators and uveitis experts, and also reached out to the FDA for guidance around an appropriate path forward. While the partial hold is in place, no new patients will be enrolled in the NUV-422 program, although current study participants may continue to be treated in the Phase 1 study. "We are committed to patient safety across all of our studies and to working collaboratively with the FDA to develop, as efficiently as possible, new medicines where existing therapies are inadequate," said David Hung, M.D., founder, president and chief executive officer of Nuvation Bio. "Based upon the recent development of uveitis as a potential safety signal, we will conduct an overall risk/benefit analysis of the NUV-422 program. Our goal is always to ensure that we deploy our resources on programs that have the highest probability of success and of generating value for patients and our investors. With $737.7 million in cash as of March 31, 2022, we are well positioned to continue developing all of our internal product candidates.

06:57 EDT McDonald's names Kevin Ozan as SEVP, strategic initiatives, Ian Borden as CFO - McDonald's Corporation CEO, Chris Kempczinski sent the following message to the McDonald's Global System, which also outlines additional leadership team updates. "McDonald's is now seen as leading in our industry on almost every dimension. Together, we've transformed the McDonald's System and are performing at a high level in almost every market in which we operate. Over the years, however, the McDonald's System has demonstrated a remarkable knack for cultivating the right leaders for the moment, and this was certainly true when Kevin Ozan and Francesca DeBiase were appointed to their roles in March 2015. Kevin and Francesca are long-time McDonald's veterans, with over forty years of combined System experience and careers that were purpose-built for their positions on our Global Senior Leadership Team. They were well-known and highly respected, and their appointments - Kevin as Chief Financial Officer and Francesca as Global Chief Supply Chain Officer - coincided with the multi-year reinvigoration of our business that has led to our current position of strength. It is with deep gratitude and respect that I am announcing today that Kevin will be assuming a new position and has been promoted to Senior Executive Vice President, Strategic Initiatives, and that Francesca recently shared with me her decision to retire from McDonald's, effective August 31. With this move, Ian Borden, currently President, International and a 30-year System veteran, has been appointed to serve as our next Executive Vice President and CFO, effective September 1. Finally,Katie Fallon, who has successfully served as McDonald's first-ever Chief Global Impact Officer, recently informed me of her decision to depart McDonald's."

06:56 EDT McDonald's names Kevin Ozan as SEVP, strategic initiatives, Ian Borden as CFO

06:52 EDT Bright Minds Biosciences names Jan Torleif Pedersen as interim CSO - Bright Minds Biosciences announced that Dr. Alan Kozikowski will no longer serve in the role of Chief Scientific Officer. Bright Minds has initiated a search for its new Chief Scientific Officer, and Jan Torleif Pedersen, PhD, MSc, a current member of the Board of Directors, will serve as the interim Chief Scientific Officer until the position is filled.

06:49 EDT TCR2 Therapeutics names Eric Sullivan as CFO - TCR2 Therapeutics announced the appointment of Eric Sullivan as CFO where he will be responsible for leading all aspects of financial management and capital market strategy as well as overseeing investor relations and select business operations. Prior to joining the company, he was President, CFO and COO at Triplet Therapeutics where he led finance, business development and corporate operations.

06:42 EDT Otis Worldwide appoints Anurag Maheshwari EVP, CFO - Otis Worldwide Corporation announces the appointment of Anurag Maheshwari as Executive Vice President & CFO, reporting directly to Otis Chair, CEO & President, Judy Marks. Effective August 12, Maheshwari will succeed Rahul Ghai, who has accepted a position outside Otis. "Anurag has championed our long-term strategy and understands how to drive growth and shareholder value. He has successfully led our finance teams in the highly diverse Asia Pacific region since spin," said Otis Chair, CEO & President, Judy Marks. "He brings deep knowledge and leadership experience with a successful track record of managing financial and operational performance, along with driving revenue, profit growth and capital deployment in publicly traded companies."

06:34 EDT BiomX announces dosing of first two patients in Phase 1b/2a study of BX004 - BiomX announced the dosing of the first two patients in the Company's Phase 1b/2a study evaluating BX004 for the treatment of chronic respiratory infections in patients with cystic fibrosis, CF. "We are pleased to reach this important clinical milestone in our cystic fibrosis program," said Jonathan Solomon, Chief Executive Officer of BiomX. "In prior in vitro studies, BX004, a novel phage cocktail targeting P. aeruginosa, demonstrated activity against antibiotic resistant strains of P. aeruginosa, as well as enhanced biofilm penetration compared to antibiotic therapies. In the first part of this study, we will assess the safety, pharmacokinetics, and clinical activity of BX004 in eight CF patients, and we look forward to discussing these data in the third quarter of 2022." BiomX is developing BX004 for the treatment of CF patients with chronic respiratory infections caused by Pseudomonas aeruginosa, a main contributor to morbidity and mortality in patients with CF. The Phase 1b/2a study of BX004 is composed of two parts. Part 1 of the study will evaluate the safety, pharmacokinetics, and microbiologic/clinical activity of BX004 in eight CF patients in a single ascending dose and multiple dose design, with results expected in the third quarter of 2022. Part 2 of the study will evaluate the safety and efficacy of BX004 in 24 CF patients randomized to a treatment or placebo cohort in a 2:1 ratio. Results from Part 2 are expected in the first quarter of 2023.

06:33 EDT Volta appoints Tang as Chief Technology Officer - Volta announced that its Board of Directors has appointed Yifan Tang as Chief Technology Officer. Tang will report directly to Vince Cubbage, Interim Chief Executive Officer. Most recently, Tang served as Chief Technology Officer and board member at SERES EV, a next-generation intelligent, autonomous EV company. He is also the co-founder of TeraWatt Technology.

06:32 EDT OppFi announces addition to Russell 2000 Index - OppFi announced the Company has been added to the Russell 2000 Index. "We are excited to join the Russell 2000 Index during our first year as a publicly-traded company," said Todd Schwartz, Chief Executive Officer and Executive Chairman of OppFi. "We believe this development will enhance our profile with investors, as we work to accomplish our mission to facilitate credit access to the 60 million Americans who are underserved by banks and other financial institutions." Effective at the market open today, in addition to the Russell 2000 Index, OppFi will be included in the Russell 3000 Index, as well as the Russell Microcap Index.

06:30 EDT Liquidia Technologies added to Russell 2000, 3000 indexes - Liquidia Corporation announced that the company was added as a member of the US small-cap Russell 2000 Index, effective after the US market opens on June 27, as part of the 2022 Russell indexes reconstitution. Membership in the Russell 2000 Index, which remains in place for one year, is based on membership in the broad-market Russell 3000 Index. The stock also was automatically added to the appropriate growth and value indexes.

06:19 EDT AstraZeneca's Lynparza recommended for E.U. approval by CHMP in breast cancer - The company states: "AstraZeneca (AZN) and MSD's (MRK) Lynparza, or olaparib, has been recommended for marketing authorisation in the European Union as monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients with germline BRCA1/2 mutations who have HER2-negative high-risk early breast cancer previously treated with neoadjuvant or adjuvant chemotherapy. The Committee for Medicinal Products for Human Use, CHMP, of the European Medicines Agency based its positive opinion on results from the OlympiA Phase III trial published in The New England Journal of Medicine in June 2021. In the trial, Lynparza demonstrated a statistically significant and clinically meaningful improvement in invasive disease-free survival, reducing the risk of invasive breast cancer recurrences, new cancers, or death by 42% versus placebo (based on a hazard ratio of 0.58; 99.5% confidence interval. Lynparza also demonstrated a statistically significant and clinically meaningful improvement in overall survival, reducing the risk of death by 32% versus placebo. The safety and tolerability profile of Lynparza in this trial was in line with that observed in prior clinical trials." Reference Link

06:09 EDT Six Flags announces July 4th fest presented by Coca-Cola - Six Flags Entertainment Corporation (SIX) in partnership with Coca-Cola (KO), invites guests to the Coca-Cola July 4th Fest. Eleven Six Flags parks across the U.S. will celebrate Independence Day with special Coca-Cola July 4th Fest pricing and spectacular fireworks lighting up the sky each night. Guests can also look forward to: Saving up to $20 off passes and discount single-day tickets; the Coca-Cola "Sounds of Summer" zone; and new Patriotic Punch beverage.

06:06 EDT Acutus Medical announces FDA clearance, commercial launch of AcQCross extension - Acutus Medical announced the commercial launch of an expanded suite of left-heart access products to now include the AcQCross Qx system for use with the TruSeal and FXD delivery system for the Watchman LAAC Device.

06:04 EDT Nutex Health selected to join Russell 2000, Russell 3000 indexes - Nutex Health announced that it has been selected to join the Russell 2000 and Russell 3000 indexes after the 2022 Russell indexes annual reconstitution, effective after the US market opens on June 27.

06:02 EDT Takeda, Arrowhead announce results from Phase 2 study of fazirsiran - Takeda (TAK) and Arrowhead Pharmaceuticals (ARWR) announced that results from a Phase 2 clinical study of investigational fazirsiran for the treatment of liver disease associated with alpha-1 antitrypsin deficiency, AATD, were recently published in the New England Journal of Medicine, NEJM, and presented in an oral presentation at The International Liver Congress 2022 - The Annual Meeting of the European Association for the Study of the Liver, EASL. The NEJM article was published online ahead of print and is titled, "Fazirsiran for Liver Disease Associated with Alpha-1 Antitrypsin Deficiency." The EASL presentation was titled, "Reduction of Intra-hepatic Z-AAT Synthesis by Fazirsiran Decreases Globule Burden and Improves Histological Measures of Liver Disease in Adults with Alpha-1 Antitrypsin Deficiency." Fazirsiran is a potential first-in-class investigational RNA interference therapy designed to reduce the production of mutant alpha-1 antitrypsin protein as a potential treatment for the rare genetic liver disease associated with AATD. Z-AAT accumulation is believed to be the cause of progressive liver disease in patients with AATD. "The exciting data on fazirsiran treatment from the open label AROAAT-2002 Phase 2 study in patients with AATD liver disease suggest a treatment effect and the potential to improve multiple downstream markers of liver health. We are also nearing completion of the Phase 2 SEQUOIA study and we look forward to further assessing the potential of fazirsiran in this larger placebo-controlled study," said Javier San Martin, M.D., Chief Medical Officer at Arrowhead. "Fazirsiran has shown a high level of activity across all patients studied and is representative of how the RNA interference pathway can be leveraged to reliably and consistently silence gene expression and potentially have a positive impact on patients with various genetic diseases."

05:41 EDT AstraZeneca, Daiichi Sankyo's Trastuzumab Deruxtecan recommended for approval - Daiichi Sankyo (DSNKY) and AstraZeneca's (AZN) trastuzumab deruxtecan has been recommended for approval in the European Union as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive breast cancer who have received one or more prior anti-HER2-based regimens. The Committee for Medicinal Products for Human Use of the European Medicines Agency based its positive opinion on results from the DESTINY-Breast03 phase 3 trial, which were published in The New England Journal of Medicine. In the DESTINY-Breast03 trial, trastuzumab deruxtecan reduced the risk of disease progression or death by 72% versus trastuzumab emtansine in patients with HER2 positive unresectable and/or metastatic breast cancer previously treated with trastuzumab and a taxane. The median progression-free survival for patients treated with trastuzumab deruxtecan was not reached compared to 6.8 months for T-DM1 as assessed by blinded independent central review. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU.

05:38 EDT Epizyme to be acquired by Ipsen for $1.45 per share plus CVR of $1.00 per share - Ipsen (IPSEY) and Epizyme (EPZM) announced that they have entered into a definitive merger agreement under which Ipsen will acquire Epizyme. The transaction was unanimously approved by both Ipsen and Epizyme Boards of Directors and is anticipated to close by the end of the third quarter of 2022, subject to the satisfaction of all closing conditions. The acquisition of Epizyme will immediately provide incremental sales and will leverage the U.S. commercial infrastructure. Given the level of ongoing R&D expenses, the transaction is expected to be moderately dilutive on Ipsen's core operating income until the end of 2024. This is in line with Ipsen's medium-term outlook regarding its strategic focus on building a high-value and sustainable pipeline through external innovation. The dilutive impact on 2022 core operating margin will be limited, given the expected timing of the transaction. The acquisition of Epizyme will immediately provide incremental sales and will leverage the U.S. commercial infrastructure. The Board of Directors of Epizyme has unanimously approved the transaction and recommended that the stockholders of Epizyme tender their shares in the tender offer. Royalty Pharma, Epizyme's largest stockholder with approximately 20.5% of Epizyme's total shares of common stock outstanding (on a non-diluted basis) as of the date hereof, has entered into a support agreement with Ipsen pursuant to which it has agreed to tender its shares in the tender offer. Under the terms of the agreement and plan of merger, Ipsen, through a subsidiary, will initiate a tender offer to acquire all outstanding shares of Epizyme at a price of $1.45 per share in cash at the closing of the transaction, for an initial estimated aggregate consideration of $247M plus one contingent value right per share. Each CVR will entitle its holder to deferred cash payments of $0.30 per CVR payable upon the first achievement of $250M in aggregate net sales of Tazverik in any period of four consecutive quarters, by 31 December 2026 and $0.70 per CVR payable upon receipt of U.S. regulatory approval necessary for the commercial marketing and sale of the combination of Tazverik and R in second-line follicular lymphoma by 1 January 2028. The $1.45 per share cash consideration represents a premium of approximately 144% compared to Epizyme's average closing price of $0.60 over the 30 trading days preceding announcement of the transaction. The transaction will be fully financed by Ipsen's existing cash and lines of credit. The closing of the tender offer will be subject to customary conditions, including the tender of shares representing at least a majority of the total number of Epizyme's outstanding shares, the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act and other customary conditions. Upon the successful completion of the tender offer, Ipsen would acquire all shares not acquired in the tender through a second-step merger for the same consideration as the tendering shareholders.

05:34 EDT Sandvik to acquire PCD tools manufacturer Frezite - Sandvik has signed an agreement to acquire 100% of the equity interests of the Portugal-based company Frezigest, SGPS. Frezite's offering primarily consists of made-to-order polycrystalline diamond tools for metal and wood applications, with exposure to the automotive, general engineering and aerospace segments. The company will be reported within Walter, a division within Sandvik Manufacturing and Machining Solutions. The parties have agreed not to disclose the purchase price. The transaction is expected to close during the third quarter of 2022 and is subject to customary closing conditions.

05:32 EDT Hexagon AB announces Paolo Guglielmini to succeed Ola Rollen as CEO - Hexagon AB announced that Paolo Guglielmini will succeed Ola Rollen as President and CEO of Hexagon AB, effective 31 December 2022. Gun Nilsson has decided to step down as CEO for Hexagon's principal shareholder MSAB on 1 October and consequently leave her position as Chairman of Hexagon AB at the Annual General Meeting 2023. MSAB, in consultation with Hexagon's nomination committee, has the intention to propose Ola Rollen as new Chairman of the Board at the AGM 2023. Paolo Guglielmini is currently Hexagon's COO and President of Hexagon's Manufacturing Intelligence division.

05:27 EDT Astellas Pharma says FDA places clinical hold on FORTIS Phase 1/2 trial - Astellas Pharma announced that the US Food and Drug Administration has placed a clinical hold on the FORTIS Phase 1/2 trial following the occurrence of a serious adverse event of peripheral sensory neuropathy in one of the trial participants. FORTIS is a clinical trial evaluating AT845, an investigational adeno-associated virus gene replacement therapy in adults with Late-Onset Pompe Disease. The FDA informed Astellas that it did not have sufficient information to assess the risks to subjects and requires additional information about the recently reported SAE. To date, the SAE has been classified by the site investigator as Grade 1 and deemed serious due to medical significance. A written explanation for the basis of the hold will be issued by the FDA and sent to Astellas within the next 30 days. Astellas is working with the site investigator to closely follow the patient's clinical course and will continue to gather and review all relevant data. All currently enrolled participants will continue to be monitored closely per the study protocol. "Patient safety is our top priority, and we are working closely with the FDA to determine appropriate next steps," explained Weston Miller, M.D., Senior Medical Director, Clinical Development at Astellas Gene Therapies. "We remain committed to the safe and effective development of AT845 and will keep the scientific and patient communities informed with updates as we learn more." Astellas is reviewing potential financial impacts of this matter for the fiscal year ending March 31, 2023.